

MEDICAL POLICY



MEDICAL POLICY DETAILS	
Medical Policy Title	FIRST TRIMESTER SCREENING FOR DOWN SYNDROME
Policy Number	2.02.25
Category	Laboratory Test
Effective Date	11/18/04
Revised Date	09/15/05, 07/20/06, 08/16/07, 08/21/08, 02/19/09, 04/21/11, 03/15/12, 03/21/13, 06/20/13, 07/17/14, 03/19/15, 03/17/16, 06/15/17, 03/15/18, 03/21/19
Archived Date	(ARCHIVED DATE: 02/18/10-4/21/11)
Product Disclaimer	<ul style="list-style-type: none"> • If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. • If a commercial product (including an Essential Plan product) or a Medicaid product covers a specific service, medical policy criteria apply to the benefit. • If a Medicare product covers a specific service, and there is no national or local Medicare coverage decision for the service, medical policy criteria apply to the benefit.

POLICY STATEMENT

- I. Based upon our criteria and review of the peer-reviewed literature, first-trimester screening for detection of Down syndrome, consisting of a calculation of risk based on maternal age, human chorionic gonadotropin, pregnancy-associated plasma protein A and ultrasonic measurement of fetal nuchal translucency, is considered to be effective and therefore **medically appropriate** for women who make a shared decision to undergo testing and desire information on the risk of having a child with Down syndrome, after informed discussions with a practitioner and adequate counseling.
- II. Based upon our criteria and review of the peer-reviewed literature, first-trimester screening for detection of Down syndrome using measurement of nuchal translucency alone has not been proven to be effective and is therefore **not medically necessary**.
- III. Based upon our criteria and review of the peer-reviewed literature, noninvasive prenatal testing (NIPT) using sequencing-based testing of maternal serum is considered **medically appropriate regardless of risk in women with singleton pregnancies undergoing screening for trisomy 21**. Concurrent nucleic acid sequencing-based testing of maternal plasma for trisomy 13 and/or 18 may be performed with the trisomy 21 screening analysis.
- IV. Based upon our criteria and review of the peer-reviewed literature, noninvasive prenatal testing (NIPT) using sequencing-based testing of maternal serum for trisomy 13 and/or 18 is considered **investigational** unless performed with trisomy 21 screening analysis.
- V. Based upon our criteria and review of the peer-reviewed literature, noninvasive prenatal testing (NIPT) using sequencing-based testing of maternal serum is considered **investigational** in women with twin or multiple pregnancies.
- VI. Based upon our criteria and review of the peer-reviewed literature, noninvasive prenatal testing (NIPT) using nucleic acid sequencing-based testing of maternal plasma for microdeletions is considered **investigational**.
- VII. Based upon our criteria and review of the peer-reviewed literature, noninvasive prenatal testing (NIPT) using nucleic acid sequencing-based testing of maternal plasma for sex chromosome aneuploidy (SCA) is considered **investigational**.
- VIII. Based upon our criteria and review of the peer-reviewed literature, first-trimester screening for detection of Down syndrome using fetal nasal bone length assessment is **investigational** in all situations.

Refer to Corporate Medical Policy #2.02.03 regarding Genetic Testing for Inherited Disorders.

Refer to Corporate Medical Policy #4.01.03 regarding Prenatal Genetic Testing and Counseling.

Medical Policy: FIRST TRIMESTER SCREENING FOR DOWN SYNDROME

Policy Number: 2.02.25

Page: 2 of 9

POLICY GUIDELINES

- I. Down syndrome risk assessment in multiple gestation using first- or second-trimester *serum analytes* is less accurate than in singleton pregnancies.
- II. NIPT should only be offered in the context of informed consent, education, and counseling by a qualified provider, such as a certified genetic counselor. Abnormal nucleic acid sequencing-based tests should be confirmed with chorionic villi sampling (CVS) or amniocentesis to exclude the possibility of a false positive NIPT result.

DESCRIPTION

Many types of biologic markers have been investigated for detection of Down syndrome fetuses. Commonly used testing has been second-trimester screening consisting of four serum markers: alpha-fetoprotein (AFP), human chorionic gonadotropin (HCG), unconjugated estriol (E3) and Inhibin-A. Women who screened positive are at an increased risk for having a child with Down syndrome.

Serum analytes: *Free beta subunit of human chorionic gonadotropin (B-hCG)* is the *b*-subunit, an amino acid sequence, unique to HCG which is a glycoprotein hormone normally produced by the developing placenta. This tends to be increased in Down syndrome. *Pregnancy-associated plasma protein-A (PAPP-A or PAPP-A)* is a protein that acts as an enzyme, and tends to be decreased in Down syndrome.

Nuchal Translucency (NT): Fetal *nuchal translucency* refers to the ultrasound detection of subcutaneous edema in the fetal neck, and is measured between the inner aspect of the fetal skin and the outer aspect of the soft tissue overlying the cervical spine or the occipital bone.

Measurement of NT has allowed for earlier, noninvasive screening for chromosomal abnormalities and, when combined with serum analyte screening in the first trimester, has comparable detection rates as standard second-trimester screening. This combined first-trimester screening method includes measurement of NT, *B-hCG*, and PAPP-A.

Fetal Nasal Bone (FNB): The absence of fetal nasal bone is considered to be a positive test result, indicating an increased risk of Down syndrome. The inability to visualize the nasal bone is regarded as an unsuccessful examination, rather than a positive test result. Fetal nasal bone examination can be done from 11 weeks to just before 14 weeks' gestation. It is sometimes recommended that, if the nasal bone is absent on ultrasound done between 11 and 12 weeks' gestation, a second examination be done two (2) weeks later.

Non Invasive Prenatal Testing (NIPT): NIPT refers to detection of trisomy 21 from fetal cell-free DNA (cfDNA) fragments present in the plasma of pregnant women. NIPT differs from ultrasound and maternal serum biomarkers because it utilizes fetal genetic material or fetal cell-free DNA rather than phenotypic features. NIPT differs from chorionic villus sampling and amniocentesis because it is non-invasive and carries no risk of miscarriage. Fetal DNA fragments are thought to be derived mainly from the placenta and may account for 6-10% or more of the total free cell DNA found in the maternal serum. NIPT is attractive because it is noninvasive and can be used to detect trisomy 21 as early as 8 to 10 weeks of gestation. Fetal cell-free DNA is measured using a technique called massively parallel sequencing (MPS) which can identify and quantify millions of cfDNA fragments. Identification may be accomplished by comparison to the human genome or DNA found specific only to the fetus. In trisomy 21, once the DNA fragments have been identified, any increase in the amount of the chromosome will indicate there is an additional copy, the test is positive and the diagnosis of trisomy 21 is made. MPS can be performed either randomly from the entire genome or selectively to evaluate specific genomic fragments. Random selection is associated with higher complexity and increased costs compared to chromosome-selective sequencing. NIPT is also being evaluated to detect Trisomy 18 and 13. NIPT was first recommended by The American College of Obstetricians and Gynecologists (ACOG) (2013) for women that are high-risk of delivering babies with Down syndrome and trisomies 13 and 18. Women age 35 years or older at delivery, history of previous pregnancy with a trisomy, parental balanced Robertsonian translocation with increased risk of fetal trisomy 13 or trisomy 21, fetal ultrasonographic findings indicating increased risk of aneuploidy (abnormal chromosome number), and standard serum screening test positive for aneuploidy are considered high-risk.

Medical Policy: FIRST TRIMESTER SCREENING FOR DOWN SYNDROME

Policy Number: 2.02.25

Page: 3 of 9

Currently there are 4 commercial tests available for screening of Trisomy 21; the MaterniT21™ (Sequenom, San Diego, CA), Verify® (Verinata Health, Redwood, CA), Harmony™ (Ariosa Diagnostics, San Jose, CA), and the Panorama™ (Natera, San Carlos, CA).

First-trimester screening offers several potential advantages over second-trimester screening. When test results are negative, it may help reduce maternal anxiety earlier. If results are positive, it allows women to take advantage of first-trimester prenatal diagnosis by chorionic villus sampling (CVS) at 10-12 weeks or second-trimester amniocentesis (greater than 15 weeks) to determine if the fetus is affected, since screening tests can give false positive results. Detecting problems earlier in the pregnancy may allow women to prepare for a child with health problems. It also affords women greater privacy and less health risk if they elect to terminate the pregnancy.

RATIONALE

When first-trimester screening combines nuchal translucency with measurement of beta-hCG and PAPP-A, the Down syndrome detection and positive screening rates are comparable to those seen with standard second-trimester screening. Measurement of nuchal translucency by itself to screen for Down syndrome is not recommended because it has a high positive screen rate when used without serum markers.

Two large, multicenter studies, the SURUSS (Serum, Urine and Ultrasound Screening) study and the BUN (Biochemistry, Ultrasound and Nuchal Translucency) study, show similar or greater estimates of sensitivity of first-trimester screening when compared either directly to second-trimester screening or historical estimates of second-trimester screening. The SURUSS study demonstrated that nuchal translucency assessment alone is inferior to either second-trimester or first-trimester combined screening.

Results of the FASTER (First and Second Trimester Evaluation of Risk) trial, sponsored by the National Institute of Child Health and Human Development are pending, however, preliminary results indicate that first-trimester combined screening at 11 weeks gestation is better than second-trimester quadruple screening. FASTER was a multicenter (15 U.S. hospitals), prospective study comparing the rates of detection of first and second-trimester noninvasive screening methods for Down syndrome for singleton pregnancies. Women underwent first-trimester screening consisting of NT thickness together with maternal age, serum levels of PAPP-A and B-hCG at 11, 12 and 13 weeks gestation, and then underwent screening again at 15-18 weeks gestation. Patients were not informed of the results of first-trimester screening until after second-trimester screening was completed. Of 38,167 women, a total of 117 fetuses were identified as having Down syndrome. Researchers compared the results of (1) first-trimester combined screening, (2) second semester screening, (3) stepwise sequential screening with results provided after each test, (4) fully integrated screening with a single result provided, and (5) serum integrated screen identical to fully integrated screening but without nuchal translucency. Rates of detection using first-trimester combined screening were: 87% at 11 weeks, 85% at 12 weeks, and 82% at 13 weeks. Rate of detection using second-trimester screening was 81%. Rate of detection using first trimester stepwise sequential screening was 95%, using serum integrated screening was 88% and using fully integrated screening was 96%. Both stepwise sequential screening and fully integrated screening techniques had high rates of detection with low false positive rates. Further research is needed to determine the most effective method of sequential screening.

Studies have found a high rate of successful imaging of the fetal nasal bone and an association between absent nasal bone and the presence of Down syndrome in high-risk populations. However, there is insufficient evidence on the performance of fetal nasal bone assessment in average-risk populations. Of particular concern is the low performance of fetal nasal bone assessment in a subsample of the FASTER study conducted in a general population sample. Two studies conducted outside of the U.S. have found that, when added to a first-trimester screening program evaluating maternal serum markers and nuchal translucency, fetal nasal bone assessment can result in a modest decrease in the false-positive rate. Several experts in the field are proposing that fetal nasal bone assessment be used as a second stage of screening, to screen women found to be of borderline risk using maternal serum markers and nuchal translucency. Additional studies using this contingent approach are needed before conclusions can be drawn about its utility. In summary, given the uncertainty of test performance in average-risk populations and the lack of standardization in the approach to incorporating this test into a first-trimester screening program, detection of fetal nasal bone is considered investigational.

A 2013 Blue Cross Blue Shield TEC Assessment of DNA sequencing-based testing of maternal plasma for trisomy 21 focused on 3 parameters: 1) analytic validity; 2) clinical validity (i.e., sensitivity and specificity) in appropriate

Medical Policy: FIRST TRIMESTER SCREENING FOR DOWN SYNDROME

Policy Number: 2.02.25

Page: 4 of 9

populations of patients; and 3) demonstration that the diagnostic information can be used to improve patient health outcomes (clinical utility). The Assessment concluded that while all commercially available tests use MPS with varying actual performance and interpretive procedures, the analytic performance metrics and the routine quality control procedures used for each of these tests has not been published. Thus there is insufficient evidence to support the analytic validity of the tests. Very high sensitivity and specificity of maternal plasma DNA sequencing-based tests for detecting trisomy 21 in high-risk women with singleton pregnancies has been reported in data from eight (8) studies. However, only one of these studies included women at average-risk of trisomy 21. Thus, there is sufficient evidence that the tests are accurate when used in women with high-risk pregnancies, but insufficient evidence on women with average-risk pregnancies or those women with multiple pregnancies. There is no published direct evidence that managing patients using sequencing-based testing improves health outcomes compared to standard screening. Modeling studies using published estimates of diagnostic accuracy and other parameters predict that sequencing-based testing as an alternative to standard screening will lead to an increase in the number of Down syndrome cases detected and a large decrease in the number of invasive tests and associated miscarriages. In summary, based on the available evidence, including modeling in the TEC assessment, as well as input from clinical vetting and recommendations from ACOG, nucleic acid sequencing-based testing for trisomy 21 may be considered medically necessary in women with high-risk singleton pregnancies who meet criteria and not medically necessary in women with average-risk singleton pregnancies.

A 2014 Blue Cross Blue Shield TEC Assessment suggests similar rates of T13 and T18 detection to standard noninvasive screening; the analysis assumed that T13 and T18 screening would be done in conjunction with T21 screening. Due to the low survival rate, the clinical benefit of identifying trisomy 18 and 13 are unclear. The clinical utility of early sex chromosome aneuploidy detection is also unclear. Thus, sequencing-based tests for T18 and T13 are considered medically necessary in women who are eligible for and are undergoing sequencing-based testing of maternal plasma for T21. Otherwise, sequencing-based testing for fetal sex chromosome aneuploidies and chromosomal microdeletions have unacceptably low positive predictive values, and therefore are considered investigational.

Several studies have evaluated the performance of cell-free DNA testing in dizygotic twin gestations. While most have concluded that cfDNA testing is feasible, all studies have identified a lower rate of reported results when compared to singletons. For example, a review by Sarno concluded that failure rate of cell-free DNA screening is higher in twin pregnancies (9.4% versus 2.9% for singletons; this is directly correlated with a lower fetal fraction of DNA in maternal serum), and that the number of trisomic dizygotic twin pregnancies in their cohort was too small for an accurate assessment of performance of the screening test. In monozygotic twins, the performance of cell-free DNA screening is similar to singleton gestations.

Professional organizations.

In November 2012, the American College of Obstetricians and Gynecologists (ACOG) released a committee opinion on noninvasive testing for fetal aneuploidy. The Committee Opinion was issued jointly with the Society for Maternal-Fetal Medicine Publications Committee. ACOG recommended that maternal plasma DNA testing be offered to patients at increased risk of fetal aneuploidy. They did not recommend that the test be offered to women who are not at high risk or women with multiple gestations. ACOG further recommended that women be counseled prior to testing about the limitations of the test and recommended confirmation of positive findings with CVS or amniocentesis. The document noted that the content reflected emerging clinical and scientific advances and is subject to change as additional information becomes available. The Committee Opinion did not include an explicit review of the literature.

The American College of Obstetricians and Gynecologists (ACOG) released a committee opinion on cell-free DNA screening for fetal aneuploidy (September 2015). The Committee Opinion concluded that noninvasive prenatal screening that uses cell-free DNA from the plasma of pregnant women offers tremendous potential as a screening method for fetal aneuploidy. Women whose results are not reported, indeterminate, or uninterpretable (a “no call” test result) from cell-free DNA screening should receive further genetic counseling and be offered comprehensive ultrasound evaluation and diagnostic testing because of an increased risk of aneuploidy. Patients should be counseled that cell-free DNA screening does not replace the precision obtained with diagnostic tests, such as chorionic villus sampling or amniocentesis and, therefore, is limited in its ability to identify all chromosome abnormalities. Cell-free DNA screening does not assess risk of fetal anomalies such as neural tube defects or ventral wall defects. Patients who are undergoing cell-free DNA screening should be offered maternal serum alpha-fetoprotein screening or ultrasound evaluation for risk assessment. The cell-free DNA screening test should not be considered in isolation from other clinical findings and test results.

Medical Policy: FIRST TRIMESTER SCREENING FOR DOWN SYNDROME

Policy Number: 2.02.25

Page: 5 of 9

Management decisions, including termination of the pregnancy, should not be based on the results of the cell-free DNA screening alone. Patients should be counseled that a negative cell-free DNA test result does not ensure an unaffected pregnancy. Given the performance of conventional screening methods, the limitations of cell-free DNA screening performance, and the limited data on cost-effectiveness in the low-risk obstetric population, conventional screening methods remain the most appropriate choice for first-line screening for most women in the general obstetric population.

In May 2016 The American College of Obstetricians and Gynecologists (ACOG) updated Practice Bulletin No. 163, "Screening for Fetal Aneuploidy," which recommends first-trimester screening using nuchal translucency and maternal serum markers with a Level A rating (based on good and consistent scientific evidence). ACOG recommends all women should be offered the option of aneuploidy screening or diagnostic testing for fetal genetic disorders, regardless of maternal age or risk factors. The choice of screening test is affected by many factors, including a desire for information before delivery, prior obstetric history, family history and the number of fetuses. No one test is superior for all test characteristics and not every test is available at all centers. Each test has advantages and disadvantages that should be discussed with each patient, with the appropriate test offered based on her concerns, needs, and values. Regardless of which screening tests are offered, information about the detection (sensitivity) and positive screening and false positive-rates, advantages, disadvantages and limitations should be communicated to the patient. It states that combined testing is an effective screening test for Down syndrome in the general population. The bulletin noted that measurement of nuchal translucency alone is less effective for first-trimester screening than is the combined test, also with a Level A rating. Additionally, this bulletin states that specific training, standardization, use of appropriate ultrasound equipment, and ongoing quality assessment are important to achieve optimal nuchal translucency measurement for Down syndrome risk assessment, and this procedure should be limited to centers and individuals meeting these criteria. This practice bulletin replaces previous ACOG bulletin No. 77 published in 2007 and Committee Opinion No. 296 published July 2004.

In a committee opinion published in December 2016, ACOG affirmed that cell-free DNA screening tests for microdeletions have not been validated clinically and are not recommended at this time. This is endorsed by the Society of Maternal-Fetal Medicine.

The position statement from the Aneuploidy Screening Committee on behalf of the Board of the International Society for Prenatal Diagnosis has concluded that reliable noninvasive maternal cell-free DNA (cfDNA) aneuploidy screening methods have only been reported for trisomies 21 and 18. cfDNA screening results have been reported for trisomy 13, but the numbers are not large and efficacy appears to be less than for trisomies 21 and 18. cfDNA screening results have also been reported for sex chromosome aneuploidy, and the efficacy is unacceptably low. There is insufficient evidence that any one cfDNA screening method is most effective, its use in low-risk populations, use in multiple gestation pregnancies, or how informative a repeat test would be in women with insufficient fetal cfDNA or a failed or uninterpretable test. In cases where mosaicism is present (including confined placental mosaicism), results may be inaccurate. This type of testing is not considered fully diagnostic and is not a replacement for amniocentesis and CVS.

The National Society of Genetic Counselors (2013) currently supports Noninvasive Prenatal Testing/Noninvasive Prenatal Diagnosis (NIPT/NIPD) as an option for patients whose pregnancies are considered to be at an increased risk for certain chromosome abnormalities. NSGC urges that NIPT/NIPD only be offered in the context of informed consent, education, and counseling by a qualified provider, such as a certified genetic counselor. Patients whose NIPT/NIPD results are abnormal, or who have other factors suggestive of a chromosome abnormality, should receive genetic counseling and be given the option of standard confirmatory diagnostic testing.

The American College of Medical Genetics (ACMG) and Genomics Position Statement for Noninvasive prenatal screening (NIPS) for fetal aneuploidy, 2016 update recommends informing all pregnant women that NIPS is the most sensitive screening option for traditionally screened aneuploidies (i.e., Patau, Edwards, and Down syndromes). They also recommend referring patients to a trained genetics professional when an increased risk of aneuploidy is reported after NIPS and offering diagnostic testing when a positive screening test result is reported after NIPS. Accurate, balanced, up-to-date information, at an appropriate literacy level when a fetus is diagnosed with a chromosomal or genomic variation in an effort to educate prospective parents about the condition of concern should be provided. These materials should reflect the medical and psychosocial implications of the diagnosis. ACMG does not recommend NIPS to screen for autosomal aneuploidies other than those involving chromosomes 13, 18, and 21.

Medical Policy: FIRST TRIMESTER SCREENING FOR DOWN SYNDROME**Policy Number: 2.02.25****Page: 6 of 9**

Multiple gestations: The May 2016 ACOG practice bulletin states while first and second trimester serum analyte screening is less sensitive in pregnancies with multiple gestations, serum analyte screening remains an acceptable option for screening in dizygotic twin gestations. There is little data to guide screening in higher order multiples.

CODES

- *Eligibility for reimbursement is based upon the benefits set forth in the member's subscriber contract.*
- ***CODES MAY NOT BE COVERED UNDER ALL CIRCUMSTANCES. PLEASE READ THE POLICY AND GUIDELINES STATEMENTS CAREFULLY.***
- *Codes may not be all inclusive as the AMA and CMS code updates may occur more frequently than policy updates.*

CPT Codes

Code	Description
76813	Ultrasound, pregnant uterus, real time with image documentation, first trimester fetal nuchal translucency measurement, transabdominal or transvaginal approach; single or first gestation (*only in conjunction with 84163 / 84704).
76814	Ultrasound, pregnant uterus, real time with image documentation, first trimester fetal nuchal translucency measurement, transabdominal or transvaginal approach; each additional gestation (list separately in addition to code for primary procedure) (*only in conjunction with 84163 / 84704).
81420	Fetal chromosomal aneuploidy (e.g., trisomy 21, monosomy X), genomic sequence analysis panel, circulating cell-free fetal DNA in maternal blood, must include analysis of chromosome 13, 18, and 21
81422 (E/I)	Fetal chromosomal microdeletion(s) genomic sequenc analysis (e.g., DiGeorge syndrome, Cri-du-chat syndrome), circulating cell-free fetal DNA in a maternal blood
81479	Unlisted molecular pathology procedure
81507	Fetal aneuploidy (trisomy 21, 18, and 13) DNA sequence analysis of selected regions using maternal plasma, algorithm reported as a risk score for each trisomy
81599	Unlisted multianalyte assay with algorithmic analysis (e.g., sex chromosome aneuploidy)
84163	Pregnancy-associated plasma protein-A (PAPP-A)
84704	Gonadotropin, chorionic (hCG); free beta chain
0009M	Fetal aneuploidy (trisomy 21, and 18) DNA sequence analysis of selected regions using maternal plasma, algorithm reported as a risk score for each trisomy (VisibiliT test, Sequenom Center for Molecular Medicine, LLC)

Copyright © 2019 American Medical Association, Chicago, IL

HCPCS Codes

Code	Description
No specific code(s)	

ICD10 Codes

Code	Description
Q90.0-Q90.9	Down syndrome (code range)
Q91.0-Q91.7	Trisomy 18 and Trisomy 13 (code range)
Q92.0-Q92.5	Other trisomies and partial trisomies of the autosomes, not elsewhere classified (code range)
Q92.61-Q92.9	Marker Chromosomes (code range)
Q93.0-Q93.9	Monosomies and deletions from the autosomes, not elsewhere classified (code range)
Q95.0-Q95.9	Balanced rearrangements and structural markers, not elsewhere classified (code range)

Proprietary Information of Excellus Health Plan, Inc.

Medical Policy: FIRST TRIMESTER SCREENING FOR DOWN SYNDROME

Policy Number: 2.02.25

Page: 7 of 9

Code	Description
Q96.0-Q96.9	Turner's syndrome (code range)
Q97.0-Q97.9	Other sex chromosome abnormalities, female phenotype, not elsewhere classified
Q98.0-Q98.9	Other sex chromosome abnormalities, male phenotype, not elsewhere classified (code range)
Q99.0-Q99.9	Other chromosome abnormalities, not elsewhere classified (code range)
Z31.430- Z31.448	Encounter for procreative investigation and testing, male or female (code range)
Z31.5	Encounter for procreative genetic counseling
Z36	Encounter for antenatal screening of mother

REFERENCES

- *American College of Obstetrics and Gynecology Committee on Practice Bulletins. ACOG practice bulletin No. 163: screening for fetal aneuploidy. Obstet Gynecol 2016 May;127(5):e127-37.
- *American College of Obstetrics and Gynecology Committee on Practice Bulletins. ACOG committee opinion No. 640: Cell-free DNA screening for fetal aneuploidy. Obstet Gynecol 2015 Sep;126(3):691-2.
- * American College of Obstetrics and Gynecology. ACOG Committee opinion No. 682: Microarrays and next-generation sequencing technology: the use of advanced genetic diagnostic tools in obstetrics and gynecology. Obstet Gynecol 2016 Dec.
- * Ashoor G, et al. Chromosome-selective sequencing of maternal plasma cell-free DNA for first-trimester detection of trisomy 21 and trisomy 18. Am J Obstet Gynecol 2012;206:322.e1-5.
- Benn P, et al. Position statement from the Aneuploidy Screening Committee on behalf of the Board of the International Society for Prenatal Diagnosis. Prenat Diagn 2013 Jul;33(7):622-9.
- Beulen L, et al. The clinical utility of non-invasive prenatal testing in pregnancies with ultrasound anomalies. Ultrasound Obstet Gynecol. 2017 Jun;49(6):721-728.
- Bevilacqua E, et al. Performance of screening for aneuploidies by cell-free DNA analysis of maternal blood in twin pregnancies. Ultrasound Obstet Gynecol 2015 Jan;45(1):61-6.
- Bianchi DW, et al. Noninvasive prenatal testing and incidental detection of occult maternal malignancies. JAMA 2015 Jul 14;314(2):162-9.
- Bianchi DW, et al. DNA sequencing versus standard prenatal aneuploidy screening. NEJM 2014 Feb 27;370(9):799-808.
- BlueCross BlueShield Association. First-trimester detection of Down syndrome using fetal ultrasound assessment of nuchal translucency combined with maternal serum assessment. Medical Policy Reference Manual 4.01.14. Archived 016 Oct 13.
- BlueCross BlueShield Association, Noninvasive Prenatal Testing for Fetal Aneuploidies Using Cell-Free Fetal DNA. Medical Policy Reference Manual 4.01.21. 2018 Aug 09.
- *BlueCross BlueShield Association Technology Evaluation Center (TEC). Sequencing-based tests to determine fetal Down syndrome (trisomy 21) from maternal plasma DNA. TEC Assessments 2013; Volume 27, Tab 10.
- *BlueCross BlueShield Association Technology Evaluation Center (TEC). Noninvasive maternal plasma sequencing-based screening for fetal aneuploidies other than trisomy 21. TEC Assessments 2014; Volume 29, Tab 7.
- Dervan AP, et al. Payer decision making for next-generation sequencing-based genetic tests: insights from cell-free DNA prenatal screening. Genet Med. 2017 May;19(5):559-567.
- * Devers PL, et al. Noninvasive prenatal testing/noninvasive prenatal diagnosis: the position of the National Society of Genetic Counselors. J Genet Couns 2013 Jun;22(3):291-5.

Medical Policy: FIRST TRIMESTER SCREENING FOR DOWN SYNDROME

Policy Number: 2.02.25

Page: 8 of 9

- *Evans MI, et al. Meta-analysis of first trimester Down syndrome screening studies: free beta-human chorionic gonadotropin significantly outperforms intact human chorionic gonadotropin in a multimarker protocol. Am J Obstet Gynecol 2007 Mar;196(3):198-205.
- Gil MM, et al. Analysis of cell-free DNA in maternal blood in screening for fetal aneuploidies: updated meta-analysis. Ultrasound Obstet Gynecol 2015 Mar;45(3):249-66.
- * Gil MM, et al. Implementation of maternal blood cell-free DNA testing in early screening for aneuploidies. Ultrasound Obstet Gynecol 2013;42(1):34-40.
- * Gregg AR, et al. ACMG statement on noninvasive prenatal screening for fetal aneuploidy. Genet Med 2013 May;15(5):395-8.
- Gregg AR, et al. Noninvasive prenatal screening for fetal aneuploidy, 2016 update: a position statement of the American College of Medical Genetics and Genomics. Genet Med. 2016 Oct;18(10):1056-65.
- Huang X, et al. Noninvasive prenatal testing of trisomies 21 and 18 by massively parallel sequencing of maternal plasma DNA in twin pregnancies. Prenat Diagn 2014 Apr;35(4):335-40.
- Larion S, et al. Use of combined first-trimester screen in high- and low-risk patient populations after introduction of noninvasive prenatal testing. J Ultrasound Med 2015 Aug;34(8):1423-8.
- Malan V, et al. Effect of cell-free DNA screening vs direct invasive diagnosis on miscarriage rates in women with pregnancies at high risk of trisomy 21: a randomized clinical trial. JAMA. 2018 Aug 14;320(6):557-565.
- *Malone FD, et al. for the FASTER Research Consortium. First-trimester nasal bone evaluation for aneuploidy in the general population. Am Coll Obstet Gynecol 2004;104(6):1222-8.
- *Nicolaidis KH, et al. Validation of targeted sequencing of single-nucleotide polymorphisms for non-invasive prenatal detection of aneuploidy of chromosomes 13, 18, 21, X, and Y. Prenat Diagn 2013;33(6):575-9.
- *Norton ME, et al. Non-Invasive Chromosomal Evaluation (NICE) Study: results of a multicenter prospective cohort study for detection of fetal trisomy 21 and trisomy 18. Am J Obstet Gynecol 2012;207:137.e1-8.
- *Ohno M, et al. The role of noninvasive prenatal testing as a diagnostic versus a screening tool--a cost-effectiveness analysis. Prenat Diagn 2013;33(7):630-5.
- *Palomaki GE, et al. DNA sequencing of maternal plasma to detect Down syndrome: An international clinical validation study. Genet Med 2011;13(11):913-20.
- Petersen, Andrea K. et al. Positive predictive value estimates for cell-free noninvasive prenatal screening from data of a large referral genetic diagnostic laboratory. Am J Obstet Gynecol. 2017 Dec; 217(6): 691.e1-691.e6
- *Rao RR, et al. The value of the first trimester ultrasound in the era of cell free DNA screening. Prenat Diagn 2016 Dec;36(13):1192-1198.
- *Rosen T, et al. For the Maternal Fetal Medicine Foundation Nuchal Translucency Oversight Committee. First trimester ultrasound assessment of the nasal bone to screen for aneuploidy. Obstet Gynecol 2007;110(2 pt 1):399-404.
- *Sahota DS, et al. Comparison of first trimester contingent screening strategies for Down syndrome. Ultrasound Obstet Gynecol 2010 Mar;35(3):286-91.
- Sarno L, Revello R, Hanson E, Akolekar R, Nicolaidis KH. Prospective first-trimester screening for trisomies by cell-free DNA testing of maternal blood in twin pregnancy. Ultrasound Obstet Gynecol. 2016 Jun;47(6):705-11.
- Shaffer BL and Norton ME. Cell-free DNA screening for aneuploidy and microdeletion syndromes. Obstet Gynecol Clin North Am. 2018 Mar;45(1):13-26.
- *Tan Y, et al. Noninvasive prenatal testing (NIPT) in twin pregnancies with treatment of assisted reproductive techniques (ART) in a single center. Prenat Diagn 2016 Jul;36(7):672-9.

Medical Policy: FIRST TRIMESTER SCREENING FOR DOWN SYNDROME

Policy Number: 2.02.25

Page: 9 of 9

Valderramos SG, et al. Cell-free DNA screening in clinical practice: abnormal autosomal aneuploidy and microdeletion results. Am J Obstet Gynecol 2016 Nov;215(5):626.e1-626.e10.

Wan J, et al. Pregnancy outcome of autosomal aneuploidies other than common trisomies detected by noninvasive prenatal testing in routine clinical practice. Prenat Diagn. 2018 Oct;38(11):849-857.

Williams J 3rd, et al. Utilization of noninvasive prenatal testing: impact on referrals for diagnostic testing. Am J Obstet Gynecol 2015 Jul;213(1):102.e1-6.

Yagel S, et al. Noninvasive prenatal testing and fetal sonographic screening: round table discussion. J Ultrasound Med 2015 Mar;34(3):363-9.

Zhang H, et al. Noninvasive prenatal testing for trisomy 21, 18, and 13 – clinical experience from 146,958 pregnancies. Ultrasound Obstet Gynecol 2015 May;45(5):530-8.

Zhang B, Lu BY, Yu B, Zheng FX, Zhou Q, Chen YP, Zhang XQ. Noninvasive prenatal screening for fetal common sex chromosome aneuploidies from maternal blood. J Int Med Res. 2017 Apr;45(2):621-630.

*Key Article

KEY WORDS

Nuchal translucency, free beta PAPP-A, free beta PAPP, PAPP-A, cell-free fetal DNA, noninvasive prenatal testing, MaterniT21™, Verify®, Harmony™, Panorama™.

CMS COVERAGE FOR MEDICARE PRODUCT MEMBERS

There is currently no National Coverage Determination (NCD) or Local Coverage Determination (LCD) for First Trimester Screening of Down Syndrome. However, CMS considers HCG testing a covered indication in specific instances but is not addressed in relation to first trimester screening for Down syndrome.